Many payers treat asthma biologics as a class and often implement step-therapy protocols—for example requiring the use of anti-IL-5 agents first if eosinophils are >300 or omalizumab first in allergic patients—followed by dupilumab if those options fail or if the patient has multiple qualifying indications. This evidence concerns the gene IL5 and asthma.